Unraveling the analytical bottlenecks in AAV characterization: the transformative promise of NGS

“It is a platform already revolutionizing genomics and could redefine the standards of AAV vector characterization with greater resolution, scalability, and data richness...”

The evolving landscape of AAV gene therapy calls for analytical methods as innovative as the therapies themselves. Next-generation sequencing (NGS) stands out as the technology with significant potential to overcome current bottlenecks, allowing genome-level insight, greater scalability, and standardization. By thoughtfully and thoroughly adopting and validating NGS, the field can increase product understanding, further shape process optimization, and accelerate the safe and effective delivery of AAV-mediated gene therapies to patients.

Please enter your email to access content Read now